



REINSURANCE **HOT** **NEWS**

April 17, 2024

The High-Cost Specialty Drug Kynamro is no longer reinsured under the BIO case type effective 3/22/2024 since it was not approved by the FDA as of August 2019.

Per AHCCCS Financial Review the following High-Cost Specialty Drugs will no longer be reinsured under the BIO Case type effective 10/01/2024 due to underutilization:

- **Novoseven**
- **Kuvan**

